What's in Galderma R&D's pipeline?

Galderma R&D has 100 drugs in our index: 44 marketed, 0 filed, 36 in Phase 3, 18 in Phase 2, 2 in Phase 1.

Which companies overlap with Galderma R&D's portfolio?

Top competitors by shared drug class: LEO Pharma, Stiefel, a GSK Company, GlaxoSmithKline, Actavis Inc., Padagis LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/galderma-r-d.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-09 · How we verify

Galderma R&D — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Galderma R&D pipeline: 44 marketed, 0 filed, 36 Phase 3, 18 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

44 marketed 0 filed 36 Phase 3 18 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
adapalene/benzoyl peroxide	adapalene/benzoyl peroxide	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)	Dermatology
Adapalene 0.1% and Benzoyl Peroxide 2.5% gel	Adapalene 0.1% and Benzoyl Peroxide 2.5% gel	marketed
Cetaphil	Cetaphil	marketed			Other
Azzalure	Azzalure	marketed			Other
Alluzience	Alluzience	marketed			Other
Loceryl NL	Loceryl NL	marketed	Antifungal (morpholine derivative)	Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase)	Dermatology
Lidocaine 7% + Tetracaine 7% cream	Lidocaine 7% + Tetracaine 7% cream	marketed	Local anesthetic combination	Voltage-gated sodium channels	Dermatology / Pain Management
Loceryl Nail Lacquer	Loceryl Nail Lacquer	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)	Dermatology
adapalen 0.1%	adapalen 0.1%	marketed
Tazarotene 0.1% gel	Tazarotene 0.1% gel	marketed	Retinoid	Retinoid X receptor (RXR), Retinoid acid receptor (RAR)	Dermatology
Oracea	Oracea	marketed			Other
Ivermectin 1% cream (IVM)	Ivermectin 1% cream (IVM)	marketed	Antiparasitic agent	Glutamate-gated chloride channels (invertebrate-specific)	Dermatology

Therapeutic area mix

Dermatology · 68
Other · 5
Dermatology / Infectious Disease · 2
Dermatology / Pain Management · 1
Dermatology/Infectious Disease · 1
Dermatology/Oncology · 1
Dermatology; Neurology; Aesthetics · 1
Endocrinology / Diabetes · 1
Infectious Disease · 1
Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

LEO Pharma · 8 shared drug classes
Stiefel, a GSK Company · 6 shared drug classes
GlaxoSmithKline · 4 shared drug classes
Actavis Inc. · 4 shared drug classes
Padagis LLC · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Allergan · 3 shared drug classes
Bausch Health Americas, Inc. · 3 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Galderma R&D:

Cite this brief

Drug Landscape (2026). Galderma R&D — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/galderma-r-d. Accessed 2026-06-09.